Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins

Asztalos, Bela F.; Maulf, Florence Le; Dallal, Gerald E.; Stein, Evan A.; Jones, Peter H.; Horvath, Katalin V.; McTaggart, Fergus; Schaefer, Ernst J.

doi:10.1016/j.amjcard.2006.09.117

Cited by 75 publications

(44 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Changes in waist circumference were associated positively with changes in HDL-TG and inversely with changes in HDL-C. In this study, a marked loss of fat mass produced significant improvement in the HDL subpopulation profi le, which was substantially greater than we had previously reported with drug intervention therapies ( 18,41 ). Moreover, substantial weight loss was accompanied by decreases of plasma TG and of the highly atherogenic RLP-C and HDL-TG levels and by increases of HDL-C.…”

Section: Discussioncontrasting

confidence: 48%

Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women

Asztalos

Swarbrick

Schaefer

et al. 2010

The Journal of Lipid Research

View full text Add to dashboard Cite

Journal of Lipid ResearchCardiovascular disease (CVD) is the leading cause of death and disability in the United States. Obesity is associated with hypertension, diabetes, elevated triglyceride (TG) levels, and decreased HDL-cholesterol (HDL-C) levels, all acknowledged as independent CVD risk factors by the AHA ( 1 ). Obesity, defi ned by body mass index (BMI) у 30 kg/m 2 , often coexists with the metabolic syndrome, which is associated with increased CVD risk. High BMI has been associated with increased risk for the development of coronary, cerebral, and peripheral vascular disease; however, due to the coexistence of multiple risk factors, the quantitative assessment of CVD risk exclusively associated with obesity is complicated.Bariatric surgery is an effective intervention to achieve long-term marked weight reduction in patients with morbid obesity ( 2, 3 ). It has recently been published that calculated 10 year CVD risk (based on the Framingham equation) in morbidly obese subjects decreased by 1.3% 12 months after laparoscopic Roux-en-Y gastric bypass (RYGBP) surgery ( 4 ) and that substantial weight loss, following RYGBP surgery, Abstract Plasma lipoproteins and glucose homeostasis were evaluated after marked weight loss before and over 12 months following Roux-en-Y gastric-bypass (RYGBP) surgery in 19 morbidly obese women. Standard lipids, remnant-lipoprotein cholesterol (RLP-C); HDL-triglyceride (TG); apolipoproteins (apo) A-I, A-II, E, and A-I-containing HDL subpopulations; lecithin-cholesterol acyltransferase (LCAT)and cholesteryl ester transfer protein ( CETP) mass and activity; plasma glucose and insulin levels were measured before and at 1, 3, 6, and 12 months after GBP surgery. Baseline concentrations of TG, RLP-C, glucose, and insulin were signifi cantly higher in obese than in normal-weight, age-matched women, whereas HDL cholesterol (HDL-C), apoA-I, apoA-II, ␣ -1 and ␣ -2 levels were signifi cantly lower. Over 1 year, signifi cant decreases of body mass index, glucose, insulin, TG, RLP-C, HDL-TG, and pre ␤ -1 levels were observed with signifi cant increases of HDL-C and ␣ -1 levels (all P < 0.05). Changes of fat mass were correlated with those of LDL cholesterol ( P = 0.018) and LCAT mass ( P = 0.011), but not with CETP mass ( P = 0.265). Changes of fasting plasma glucose concentrations were inversely correlated with those of CETP mass ( P = 0.005) and ␣ -1 level ( P = 0.004). Changes of fasting plasma insulin concentrations were positively correlated with those of LCAT mass ( P = 0.043) and inversely with changes of ␣ -1 ( P = 0.03) and ␣ -2 ( P = 0.05) concentrations. These results demonstrate benefi cial changes in HDL remodeling following substantial weight loss induced by RYGBP surgery and that these changes are associated with improvement of glucose homeostasis in these patients. -Asztalos, B.

show abstract

Section: Discussioncontrasting

confidence: 48%

Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women

Asztalos

Swarbrick

Schaefer

et al. 2010

The Journal of Lipid Research

View full text Add to dashboard Cite

show abstract

“…Our idea that differently sized HDL particles may affect the targeting of CE produced in plasma to either atherogenic or atheroprotective targets ( 26 ) is supported by the recent fi nding that rosuvastatin therapy may induce the regression of coronary atherosclerosis by raising plasma HDL-C, specifi cally by increasing HDL particle size ( 27 ). Thus, we believe that FER HDL is a good measure of the atherogenic (or atheroprotective) pathways.…”

Section: Associations Of Fer Hdl and Aip With Changes In Coronary Artsupporting

confidence: 51%

Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography

Dobiášová

Fröhlich

Šedová

et al. 2011

Journal of Lipid Research

189

125

View full text Add to dashboard Cite

Many anthropometric, clinical, and biochemical factors can infl uence the composition and size of lipoprotein subpopulations. It has been demonstrated that the prevalence of small dense LDL particles increases cardiovascular (CV) risk ( 1-3 ) and that the distribution of differently sized particles in HDL infl uences its anti-atherogenic effects ( 4-8 ).In the HDL-Atherosclerosis Treatment Study (HATS), in which patients with coronary disease and low HDL-cholesterol (HDL-C) were treated with a combinations of simvastatin, niacin, and antioxidants, the therapy had a selective effect on composition of lipoprotein subpopulations and therefore on consequent changes in the coronary artery stenosis ( 9 ). Although the composition of lipoprotein subpopulations contributes substantially to plasma atherogenicity, it is impractical to measure its variations as the assays have not been standardized and are expensive and thus not suitable for routine use.We have established that two markers of CV risk, namely cholesterol esterifi cation rate in apolipoprotein Abstract We examined the association between rate of cholesterol esterifi cation in plasma depleted of apolipoprotein B-containing lipoproteins (FER HDL ), atherogenic index of plasma (AIP) [(log (TG/HDL-C)], concentrations, and size of lipoproteins and changes in coronary artery stenosis in participants in the HDL-Atherosclerosis Treatment Study. A total of 160 patients was treated with simvastatin (S), niacin (N), antioxidants (A) and placebo (P) in four regimens. FER HDL was measured using a radioassay; the size and concentration of lipoprotein subclasses were determined by nuclear magnetic resonance spectroscopy. The S+N and S+N+A therapy decreased AIP and FER HDL , reduced total VLDL (mostly the large and medium size particles), decreased total LDL particles (mostly the small size), and increased total HDL particles (mostly the large size). FER HDL and AIP correlated negatively with particle sizes of HDL and LDL, positively with VLDL particle size, and closely with each other ( r = 0.729). Changes in the proportions of small and large lipoprotein particles, which were refl ected by FER HDL and AIP, corresponded with fi ndings on coronary angiography. Logistic regression analysis of the changes in the coronary stenosis showed that probability of progression was best explained by FER HDL ( P = 0.005). FER HDL and AIP refl ect the actual composition of the lipoprotein spectrum and thus predict both the cardiovascular risk and effectiveness of therapy. AIP is already available for use in clinical practice as it can be readily calculated from the routine lipid profi le. -Dobiášová, M., J. Frohlich, M. Šedová, M. C. Cheung, and B. G. Brown. Cholesterol esterifi cationThe study was supported by HDL-C, HDL-cholesterol; log(TG/HDL-C), logarithmically transformed ratio of molar concentrations of triglyceride and HDL-cholesterol; N, niacin; P, placebo; S, simvastatin; TC, total cholesterol; TG, triglyceride .

show abstract

“…25 The percent change seen in any HDL subtype postintervention, despite reaching statistical significance, was more modest than in previous trials that involved non-HIV populations treated with statins, fibrates, or niacin, alone or in combination. [14][15][16] Although other lipid-lowering agents may have more of an impact on HDL subtypes, our more modest change could be due to the higher baseline antiatherogenic a-1 and a-2 and lower atherogenic a-3 levels in our cohort compared to other HAART-naive and PI-treated HIV-infected individuals. 22 In fact, our cohort more closely resembled values of healthy subjects.…”

Section: Effect Of Omega-3 Fatty Acids On Lipids In Hivmentioning

confidence: 77%

“…2,11 Some components, a-3 and prea-3, can be associated with atherogenesis and yet others, a-1 and prea-1, with a cardioprotective effect. 12,13 Additionally, certain lipidlowering agents have been shown to alter these subtypes and presumably improve the cardioprotective nature of HDL-C. [14][15][16] Most of these studies have been conducted in the non-HIV-infected population. The effects of lipid-lowering treatment on HDL subtypes in the HIV population are still largely unknown.…”

mentioning

confidence: 99%

Short Communication: Effects of Omega-3 Fatty Acids on Triglycerides and High-Density Lipoprotein Subprofiles in HIV-Infected Persons with Hypertriglyceridemia

Paranandi

Asztalos

Mangili

et al. 2014

AIDS Research and Human Retroviruses

Self Cite

View full text Add to dashboard Cite

Hypertriglyceridemia and low high-density lipoprotein (HDL)-cholesterol (HDL-C) may contribute to a presumed accelerated risk for cardiovascular disease in HIV-infected individuals. We evaluated the effect of omega-3 fatty acid treatment on triglycerides, low-density lipoprotein (LDL)-C, HDL-C, and HDL subpopulations. Forty-one HIVseropositive subjects with hypertriglyceridemia ( ‡ 150 mg/dl) on active antiretroviral therapy were enrolled in this placebo-controlled, double-blind, randomized, crossover trial comparing the effects of omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA) on triglycerides, LDL-C, HDL-C, and HDL subpopulations. An independent sample t-test was used to assess the study start to posttreatment change for all components. After omega-3 fatty acid treatment, triglyceride levels decreased 63.2 -86.9 mg/dl ( p < 0.001). No significant changes in total cholesterol, LDL-C, or HDL-C were found. Within HDL subpopulations, significant changes were seen in the most atheroprotective HDL particles, a-1, which increased by 2.5 -5.6 mg/dl ( p < 0.05), and prea-1, which increased by 0.6 -1.0 mg/dl ( p < 0.001). Prea-3, a presumably atherogenic HDL particle, decreased by 0.5 -0.9 mg/dl ( p < 0.01). Omega-3 fatty acid treatment significantly lowered triglyceride levels in HIV-positive patients with moderate hypertriglyceridemia. While no study-wide improvements in LDL-C or HDL-C were detected, the HDL subpopulation profile changed in a beneficial way suggesting more cardioprotection after treatment.

show abstract

Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins

Cited by 75 publications

References 16 publications

Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women

Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women

Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography

Short Communication: Effects of Omega-3 Fatty Acids on Triglycerides and High-Density Lipoprotein Subprofiles in HIV-Infected Persons with Hypertriglyceridemia

Contact Info

Product

Resources

About